More recently a focus on immune checkpoint inhibition has renewed major interest in a variety of strategies to manipulate the patient’s own immune system to eliminate the cancer, or at least control its clinical manifestations for extended periods of time.3,4 These clinical efforts are rapidly progressing in multiple areas, including in tumor types that were not traditionally be-lieved to be targets for immune manipulation, such as cancers of the colon5 and lung.6
Finally, it is increasingly clear that our overall knowledge of optimal strategies to effectively manipulate the immune system, either through infusion of immune-reactive T-cells, vaccination strategies, or inhibitors of immune blockage remain in their infancy. Consider, for example, recent reports suggesting the great-est benefit from inhibitors of immune blockage appears to occur in cancers that possess the largest number of individual muta-tions within the tumor,7 the observation that the composition of an individual patient’s gastrointestinal microbiology may sub-stantially impact the effectiveness of this therapeutic strategy,8 and the potential for local radiation therapy to potentiate the favorable influence of a systemic immune approach.9
For several reasons ovarian cancer is an ideal tumor type for which to consider an immune-modulatory management ap-proach. First, the cancer itself does not substantially negatively impact immune-regulatory cells that may be present within the bone marrow or other body locations. Second, while standard cytotoxic therapy of ovarian cancer can result in a depression in the number of immune-regulatory cells, these effects are gener-ally modest in extent and short in duration. Further, until late in the course of the natural history of the illness, it is common for patients with ovarian cancer to maintain a quite reasonable performance status and satisfactory nutrition (except in the pres-ence of cancer-related bowel dysfunction).
In addition, the majority of patients with ovarian cancer (even those with stage 4 disease) initially respond to cytotoxic therapy and can reasonably be anticipated to experience a period away from active treatment measured in “many months” to “many years”. This time interval would presumably be sufficient for the required “activation” of immune defense mechanisms, either from a successful vaccination strategy or other form of immune modulation.
A rather substantial pre-clinical experience has supported the theoretical potential for a variety of immunotherapeutic ap-proaches in the management of ovarian cancer, including vacci-nation and immune cell-based infusions.10-12
Perhaps the most provocative pre-clinical data in this arena was published more than a decade ago from a group of investiga-tors who noted in a retrospective analysis that ovarian cancer pa-tients whose tumors were shown to contain CD3+ T cells (54% of samples) experienced a 5-year overall survival (OS) of 38% compared to only 4.5% among the population without evidence of these cells.13 The authors further noted that the absence of intratumoral T cells was associated with a higher level of vascular endothelial growth factor (VEGF), a well-recognized growth stim-ulatory factor for ovarian cancer.
Based on the observation of potentially highly clinically relevant ovarian cancer tumor-associated antigens, investigators have ini-tiated multiple clinical trials, including a number of phase III randomized efforts, to examine a vaccine-based strategy in the malignancy.10-12 Unfortunately, to date, even though it has been shown to be possible to successfully “immunize” patients (eg, positive antibody response to the vaccine-based antigen), all such reported vaccination efforts have failed to demonstrate an im-provement in a clinically relevant outcome (eg, progression-free survival [PFS] or OS). However, active research efforts in this important arena (both pre-clinical and clinical) appropriately continue.10,11
It should be noted here that one form of “antibody-based” therapy of ovarian cancer has been shown to be clinically effec-tive, and this is the administration of the monoclonal antibody (bevacizumab) directed against VEGF.14,15 In phase III random-ized trials in several clinical settings (newly diagnosed, recurrent potentially-platinum-sensitive, platinum-resistant disease) the ad-ministration of this agent has been shown to improve PFS com-pared to cytotoxic chemotherapy alone. In contrast, several oth-er “antibody-based” therapies widely employed in other tumor types, including trastuzumab in breast cancer,16 and cetuximab in colon cancer,11 have been shown in phase II studies to have limited activity in ovarian cancer.
Despite the pre-clinical suggestion that ovarian cancer may be an excellent model with which to explore a variety of immuno-modulatory strategies, there has been quite modest reported clin-ical trial activity in this arena. To date, most of the studies have been small phase II efforts or only a few ovarian cancer patients have been included among a much larger group of patients with other cancer types undergoing therapy with a particular strategy. The unfortunate result is that only anecdotal evidence of ther-apeutic efficacy exists, including the unique approach of direct intraperitoneal delivery of a potent immunostimulatory agent, IL-2.17
Similar statements can also be made for the extent of cur-rent published evidence for a potential clinical role for im-mune-checkpoint blockade as a therapeutic strategy in ovarian cancer. A company-sponsored phase II trial of single agent ipili-mumab in ovarian cancer is scheduled for completion in approx-imately 1 year (ClinicalTrials.gov identifier: NCT01611558). An NRG study (NRG-GY003) is comparing single agent nivolumab with or without ipilimumab in a similar setting. The results of both trials are awaited with considerable interest.
There have been several reports noting objective, but to-date limited, clinical activity associated with an anti-PD-1 approach in previously treated ovarian cancer. In one report involving multiple tumor types, only one of 17 ovarian cancer patients treated with one such agent (BMS-936559) achieved an objective response.4 In the single phase II study published to date in the peer-reviewed literature and focused solely on ovarian cancer patients, an overall response rate of 15% (3 of 20 patients) was reported following treatment with the anti-PD-1 antibody nivolumab, with a median PFS of 3.5 months being observed in the trial.18 Similar response data have been noted in a preliminary report of pembrolizumab administered in a phase IB study to patients with PD-L1 positive ovarian cancer (3 of 20 patients; 15%), including two responses at up to about one year.19
While the objective response rate reported in these small trials was certainly not overly impressive, complete and durable remissions were observed in these study populations. It is reasonable to anticipate that detailed analysis of the responding patient population will provide highly relevant insight into their unique molecular and immunological characteristic that will assist in the future selection of patients most likely to benefit from this particular therapeutic strategy.
Follow-up of these reported trials, as well as additional experience with checkpoint inhibitors will absolutely be required before any definitive statements can be made regarding the potential utility of this class of agents in the routine management of advanced ovarian cancer.
While the theoretical potential of a role for immune modulation in the treatment of ovarian cancer remains very much alive, the promise has yet to be fulfilled. It is hoped that ongoing and planned studies exploring a variety of strategies to manipulate the immune system in women with ovarian cancer will ultimately demonstrate the unequivocal clinical utility of this therapeutic strategy.
Affiliation: Maurie Markman, MD, is from Cancer Treatment Centers of America, Philadelphia, PA; and Drexel University College of Medicine, Philadelphia, PA.
Address Correspondence to: Maurie Markman, MD, 1331 E Wyoming Ave, Philadelphia, PA 19124, phone: 215-537-7400; fax: 215-537-7139; email: firstname.lastname@example.org
- Rosenberg SA. CCR 20th anniversary commentary: autologous T cells-the ultimate personalized drug for the immunotherapy of human cancer. Clin Cancer Res. 2015;21(24):5410-5411. doi: 10.1158/1078-0432.CCR-14-3131.
- Tran E, Ahmadzadeh M, Lu Y-C, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387-1390. doi: 10.1126/science.aad1253.
- Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889-1894. doi: 10.1200/JCO.2014.56.2736.
- Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(266);2455-2465. doi: 10.1056/NEJMoa1200694.
- Oh DY, Venook AP, Fong L. On the verge: Immunotherapy for colorectal carcinoma. J Natl Compr Canc Netw. 2015;13(8):970-978.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2105;373(17):1627-1639. doi: 10.1056/ NEJMoa1507643.
- Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520. doi: 10.1056/NEJMoa1500596.
- Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockage relies on the gut microbiota. Science. 2015;350(6264):1079-1084. doi: 10.1126/science.aad1329.
- Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325-1332. doi: 10.1001/jamaoncol.2015.2756.
- Tse BWC, Collins A, Oehler MK, et al. Antibody-based immunotherapy for ovarian cancer: where are we at? Ann Oncol. 2014;25(2):322-31. doi: 10.1093/annonc/mdt405.
- Chester C, Dorigo O, Berek J, et al. Immunotherapeutic approaches to ovarian cancer. J Immunother Cancer. 2015;3:7. doi: 10.1186/s40425-015-0051-7.
- De Felice F, Marchetti C, Palaia I, et al. Immunotherapy of ovarian cancer: the role of checkpoint inhibitors. J Immunol Res. 2015;2015:191832. doi: 10.1155/2015/191832.
- Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213.
- Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-83. doi: 10.1056/NEJMoa1104390
- Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-8. doi: 10.1200/ JCO.2013.51.4489.
- Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-90.
- Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: 24 hour versus 7-day infusion. J Clin Oncol. 1997; 15(11):3399-3407.
- Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015 22. doi: 10.1200/JCO.2015.62.339
- Varga A, Piha-Paul SA, Ott PA, et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. J Clin Oncol. 2105;33(15)(May 20 supplement):5510.